Law Offices of Thomas J. Lamb

  • About Our Firm
  • Drug Injury
  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Breast Implants
  • Free Case Evaluation
  • FAQs

Questions Raised About Whether Fournier’s Gangrene Is A Side Effect Of Farxiga, Invokana, And Jardiance

August 19, 2019 By Law Offices of Thomas J. Lamb, P.A.

At the recent American Diabetes Association (ADA) Scientific Sessions there were reportedly questions raised about whether there is an increased risk of Fournier’s gangrene when using Farxiga as well as other SGLT2 inhibitor diabetes drugs such as Invokana and Jardiance. From this July 18, 2019 article published online by Medscape, “Fournier … [Read more...]

Filed Under: Unsafe Drugs Tagged With: diabetes drugs side effects, Farxiga, Fournier’s Gangrene, Invokana, Jardiance, SGLT-2 inhibitors, sglt2 inhibitors diabetes drugs

Cases Of Fournier Gangrene Associated With Diabetes Drugs Invokana, Jardiance, And Farxiga

May 9, 2019 By Law Offices of Thomas J. Lamb, P.A.

The FDA has identified 55 unique cases of Fournier gangrene associated with diabetes drugs in the Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors class between March 1, 2013 and January 31, 2019. Of those Fournier gangrene cases, 21 cases were associated with Invokana (canagliflozin), 18 cases were associated with Jardiance (empagliflozin), and … [Read more...]

Filed Under: Unsafe Drugs Tagged With: diabetes drugs, diabetes drugs side effects, Farxiga, Fournier’s Gangrene, Invokana, Jardiance, sglt2 inhibitors diabetes drugs

Lower Limb Amputations From All SGLT2 Inhibitors, or Just Invokana?

January 9, 2019 By Law Offices of Thomas J. Lamb, P.A.

A “Black-Box Warning” about the increased risk of lower limb amputations was added to the drug labels for Invokana and Invokamet in July 2017. Since that time there has been a mix of opinions expressed in the medical literature about whether or not lower limb amputations are a side effect of all diabetes medicines in the sodium-glucose … [Read more...]

Filed Under: Unsafe Drugs Tagged With: diabetes drugs, drug injury lawsuits, drug side effects, Farxiga, Invokamet, Invokana, Jardiance, lower limb amputations

Farxiga And Jardiance Have Two-Time Increased Risk For Amputations

November 23, 2018 By Law Offices of Thomas J. Lamb, P.A.

Patients using the diabetes drugs Farxiga and Jardiance had twice the risk for lower limb amputations relative to certain other diabetes medicines, according to a new observational study published in November 2018 by The BMJ medical journal in. However, in the US only a third diabetes drugs in the sodium-glucose cotransporter 2 (SGLT2) … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Amputations, diabetes drugs, drug injury, Farxiga, Invokamet, Invokana, Jardiance

Amputations Are Diabetes Drugs Side Effects For SGLT2 Inhibitors Class

November 7, 2018 By Law Offices of Thomas J. Lamb, P.A.

There seems to be an increasing degree of acknowledgement in the medical literature that these lower limb amputations are drug-class side effects of SGLT2 inhibitors class diabetes medicines such as Jardiance and Farxiga in addition to Invokana. For example, from this recent Medscape news report, “Canagliflozin (Invokana) Gets FDA Nod for CV … [Read more...]

Filed Under: Unsafe Drugs Tagged With: diabetes drugs, diabetes drugs amputation, drug side effects, Farxiga, Invokana, Jardiance, lower limb amputations

Lower Limbs Amputations Are SGLT-2 Inhibitors Drug-Class Side Effects

October 18, 2018 By Law Offices of Thomas J. Lamb, P.A.

New medical evidence indicates that lower limbs amputations may be a “drug-class” side effect for all of the sodium-glucose cotransporter 2 (SGLT-2) inhibitor diabetes drugs which have been approved by the FDA to date. We get the following explanation of this increased risk of toe, foot, or leg amputations for Jardiance and Farxiga as well as … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Amputations, Farxiga, Glyxambi, Invokamet, Invokana, Jardiance, Leg Amputation, Toes Amputation

Fournier’s Gangrene: Side Effect For Invokana, Farxiga, And Jardiance

October 15, 2018 By Law Offices of Thomas J. Lamb, P.A.

From this August 29, 2018 Drug Safety Communication, “FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes”, we get the following details about this new safety issue for Invokana, Farxiga, Jardiance, and similar diabetes drugs: Fournier’s gangrene is an extremely rare but life-threatening … [Read more...]

Filed Under: Unsafe Drugs Tagged With: diabetes drugs, drug injury, drug side effects, Farxiga, Fournier’s Gangrene, Invokana, Jardiance

Increased Risks Of Lower-Limb Amputations For Farxiga And Jardiance

September 5, 2018 By Law Offices of Thomas J. Lamb, P.A.

During late August a presentation at the 2018 European Society of Cardiology Congress in Munich, Germany included evidence that the SGLT-2 inhibitors Invokana, Jardiance, and Farxiga all are associated with twofold increases for lower-limb amputations when compared to GLP-1 receptor agonists diabetes drugs. An August 25, 2018 Healio.com article, … [Read more...]

Filed Under: Uncategorized, Unsafe Drugs Tagged With: Amputations, diabetes drugs, drug injury, Farxiga, Invokana, Jardiance

Invokana, Jardiance, And Farxiga Have Increased Risks Of Amputations

August 16, 2018 By Law Offices of Thomas J. Lamb, P.A.

Sodium-glucose cotransporter 2 inhibitors (SGLT-2 inhibitors) such as Invokana, Jardiance, and Farxiga have a higher risk of leg, feet, and toe amputations drug-class side effect when compared to older diabetes drugs such as sulfonylureas, metformin, and thiazolidinediones. This finding was reported in the article “Association Between … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Amputations, Farxiga, Glyxambi, Invokamet, Invokana, Jardiance, Qtern, Segluromet, Steglatro, Steglujan, Synjardy, Xigduo

New SGLT2 Inhibitor Diabetes Drugs to Hit the Market in January

December 28, 2017 By Law Offices of Thomas J. Lamb, P.A.

Approval On December 19, 2017, the FDA approved Merck & Co. and Pfizer's new diabetes drug, Steglatro, and its two combination versions, Steglujan and Segluromet.  These drugs are classified as sodium/glucose cotransporter 2 (SGLT2) inhibitors, and will be available this coming January. Steglatro consists of ertugliflozin, while Steglujan … [Read more...]

Filed Under: Unsafe Drugs Tagged With: diabetes drugs side effects, drug safety news, Farxiga, Glyxambi, Invokamet, Invokana, Jardiance, merck, new sglt2 inhibitors diabetes drugs, pfizer, Qtern, Segluromet, sglt2 inhibitors diabetes drugs, Steglatro, Steglujan, Synjardy, type 2 diabetes drugs, Xigduo

  • 1
  • 2
  • 3
  • Next Page »

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • Drug Injury Cases
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • GenX Cancer Cases
  • Breast Implant Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • About Our Firm
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2021 · Law Offices of Thomas J. Lamb, P.A.